For decades, cardiac advancements have been a hallmark of the Texas Medical Center. This legacy is being extended in an important new way with the first-in-human implantation of the BiVACOR Total Artificial Heart at The Texas Heart Institute (THI). The visionaries behind this successful implant, The Texas Heart Institute, BiVACOR, Baylor College of Medicine, and CHI St. Luke's Health - Baylor St. Luke's Medical Center, have consistently pushed boundaries to transform the landscape of cardiac care. It is an honor to provide an environment that fosters such innovations, enabling academia, healthcare, and industry to work together on breakthrough technologies. #TMC #HeartFailure #HeartDisease #CardiovascularHealth #Cardiology #MedTech
Together with The Texas Heart Institute, Baylor College of Medicine, and Texas Medical Center, we have successfully completed the first-in-human implantation of the BiVACOR Total Artificial Heart as part of the U.S. FDA Early Feasibility Study. 🎙️“I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute. Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial.” - Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR 🎙️“The Texas Heart Institute is enthused about the groundbreaking first implantation of BiVACOR’s TAH. With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant. We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.” - Dr. Joseph G. Rogers, M.D., President and Chief Executive Officer of The Texas Heart Institute and National Principal Investigator on the research. The successful implantation of BiVACOR’s TAH highlights the potential of innovative technologies to address critical challenges in cardiac care, such as long transplantation waitlists. BiVACOR and The Texas Heart Institute remain committed to advancing the field of cardiac medicine and improving outcomes for patients worldwide. Learn more about today’s announcement in our joint press release: https://lnkd.in/gBTGFqww> William Cohn Alexis Shafii #HeartFailure #HeartDisease #Cardiology #MedTech